|
US8183344B2
(en)
*
|
1996-04-24 |
2012-05-22 |
University Of Michigan |
Inactivation resistant factor VIII
|
|
US7214660B2
(en)
|
2001-10-10 |
2007-05-08 |
Neose Technologies, Inc. |
Erythropoietin: remodeling and glycoconjugation of erythropoietin
|
|
US7173003B2
(en)
|
2001-10-10 |
2007-02-06 |
Neose Technologies, Inc. |
Granulocyte colony stimulating factor: remodeling and glycoconjugation of G-CSF
|
|
US8791070B2
(en)
|
2003-04-09 |
2014-07-29 |
Novo Nordisk A/S |
Glycopegylated factor IX
|
|
NZ542586A
(en)
|
2003-04-09 |
2009-11-27 |
Biogenerix Ag |
Method of forming a covalent conjugate between a G-CSF peptide and PEG
|
|
TWI353991B
(en)
|
2003-05-06 |
2011-12-11 |
Syntonix Pharmaceuticals Inc |
Immunoglobulin chimeric monomer-dimer hybrids
|
|
WO2005012484A2
(en)
|
2003-07-25 |
2005-02-10 |
Neose Technologies, Inc. |
Antibody-toxin conjugates
|
|
US8633157B2
(en)
|
2003-11-24 |
2014-01-21 |
Novo Nordisk A/S |
Glycopegylated erythropoietin
|
|
US20080305992A1
(en)
|
2003-11-24 |
2008-12-11 |
Neose Technologies, Inc. |
Glycopegylated erythropoietin
|
|
US20060040856A1
(en)
|
2003-12-03 |
2006-02-23 |
Neose Technologies, Inc. |
Glycopegylated factor IX
|
|
CA2547569C
(en)
*
|
2003-12-03 |
2013-04-16 |
University Of Rochester |
Recombinant factor viii having increased specific activity
|
|
JP5743368B2
(ja)
|
2004-01-08 |
2015-07-01 |
ラショファーム ゲーエムベーハー |
ペプチドのｏ結合型グリコシル化
|
|
US20080300173A1
(en)
|
2004-07-13 |
2008-12-04 |
Defrees Shawn |
Branched Peg Remodeling and Glycosylation of Glucagon-Like Peptides-1 [Glp-1]
|
|
ES2566670T3
(es)
|
2004-10-29 |
2016-04-14 |
Ratiopharm Gmbh |
Remodelación y glucopegilación del factor de crecimiento de fibroblastos (FGF)
|
|
AU2006203792B2
(en)
|
2005-01-10 |
2011-11-03 |
Ratiopharm Gmbh |
Glycopegylated Granulocyte Colony Stimulating Factor
|
|
EP1871795A4
(en)
|
2005-04-08 |
2010-03-31 |
Biogenerix Ag |
COMPOSITIONS AND METHOD FOR PRODUCING GLYCOSYLATION MUTANTS OF A PROTEASE-RESISTANT HUMAN GROWTH HORMONE
|
|
JP2008537680A
(ja)
*
|
2005-04-14 |
2008-09-25 |
ツェー・エス・エル・ベーリング・ゲー・エム・ベー・ハー |
安定性の増大された改変型凝固第ｖｉｉｉ因子およびその誘導体
|
|
US20080255026A1
(en)
|
2005-05-25 |
2008-10-16 |
Glycopegylated Factor 1X |
Glycopegylated Factor Ix
|
|
US20070105755A1
(en)
|
2005-10-26 |
2007-05-10 |
Neose Technologies, Inc. |
One pot desialylation and glycopegylation of therapeutic peptides
|
|
WO2007056191A2
(en)
|
2005-11-03 |
2007-05-18 |
Neose Technologies, Inc. |
Nucleotide sugar purification using membranes
|
|
CN101379077A
(zh)
|
2005-12-07 |
2009-03-04 |
夏洛特·豪泽 |
因子ⅷ和因子ⅷ-类似蛋白的小肽或者拟肽亲合性配体
|
|
US20090203077A1
(en)
*
|
2006-06-30 |
2009-08-13 |
The Regents Of The University Of Michigan |
Method of producing factor viii proteins by recombinant methods
|
|
JP2009542225A
(ja)
*
|
2006-06-30 |
2009-12-03 |
ザ・リージエンツ・オブ・ザ・ユニバーシテイ・オブ・ミシガン |
組換え法によりｆｖｉｉｉタンパク質を生産する方法
|
|
JP2009544327A
(ja)
|
2006-07-21 |
2009-12-17 |
ノヴォ ノルディスク アー／エス |
Ｏ−結合型グリコシル化配列によるペプチドのグリコシル化
|
|
WO2008057683A2
(en)
|
2006-10-03 |
2008-05-15 |
Novo Nordisk A/S |
Methods for the purification of polypeptide conjugates
|
|
LT2126106T
(lt)
|
2007-02-23 |
2018-01-10 |
Sk Chemicals Co., Ltd. |
Viii faktoriaus ir jo darinių gavimo ir gryninimo būdas
|
|
RS52845B
(en)
|
2007-04-03 |
2013-12-31 |
Biogenerix Ag |
TREATMENT PROCEDURES USING GLYCOPEGILATED G-CSF
|
|
US9493499B2
(en)
|
2007-06-12 |
2016-11-15 |
Novo Nordisk A/S |
Process for the production of purified cytidinemonophosphate-sialic acid-polyalkylene oxide (CMP-SA-PEG) as modified nucleotide sugars via anion exchange chromatography
|
|
US8183345B2
(en)
|
2007-11-01 |
2012-05-22 |
University Of Rochester |
Recombinant factor VIII having reduced inactivation by activated protein C
|
|
CA2711503A1
(en)
*
|
2008-01-08 |
2009-07-16 |
Biogenerix Ag |
Glycoconjugation of polypeptides using oligosaccharyltransferases
|
|
RU2573587C2
(ru)
|
2008-02-27 |
2016-01-20 |
Ново Нордиск А/С |
Конъюгированные молекулы фактора viii
|
|
CN104045716A
(zh)
*
|
2008-05-16 |
2014-09-17 |
拜耳医药保健有限公司 |
靶向性凝固因子及其使用方法
|
|
EA020843B1
(ru)
|
2009-02-03 |
2015-02-27 |
Амуникс Оперейтинг Инк. |
Удлиненные рекомбинантные полипептиды и содержащие их композиции
|
|
JP2013502458A
(ja)
|
2009-08-24 |
2013-01-24 |
アムニクス オペレーティング インコーポレイテッド |
凝固第ｖｉｉ因子組成物ならびにそれを製造および使用する方法
|
|
WO2011041770A1
(en)
|
2009-10-02 |
2011-04-07 |
The Children's Hospital Of Philadelphia |
Compositions and methods for enhancing coagulation factor viii function
|
|
CN102791285A
(zh)
|
2009-12-06 |
2012-11-21 |
比奥根艾迪克依蒙菲利亚公司 |
因子VIII-Fc嵌合多肽和杂交多肽及其使用方法
|
|
WO2012006623A1
(en)
|
2010-07-09 |
2012-01-12 |
Biogen Idec Hemophilia Inc. |
Systems for factor viii processing and methods thereof
|
|
SG186875A1
(en)
|
2010-07-09 |
2013-02-28 |
Biogen Idec Hemophilia Inc |
Chimeric clotting factors
|
|
SG10201509149VA
(en)
*
|
2010-11-05 |
2015-12-30 |
Baxter Int |
A new variant of antihemophilic factor viii having increased specific activity
|
|
EP2717898B1
(en)
|
2011-06-10 |
2018-12-19 |
Bioverativ Therapeutics Inc. |
Pro-coagulant compounds and methods of use thereof
|
|
PT2729161T
(pt)
|
2011-07-08 |
2019-04-01 |
Bioverativ Therapeutics Inc |
Polipéptidos fator viii híbridos e quiméricos, e métodos de utilização dos mesmos
|
|
EP2737311B1
(en)
|
2011-07-25 |
2020-12-02 |
Bioverativ Therapeutics Inc. |
Assays to monitor bleeding disorders
|
|
EP2768522B1
(en)
|
2011-10-18 |
2016-07-27 |
CSL Behring GmbH |
Use of sulfated glycosaminoglycans for improving the bioavailability of factor viii
|
|
US9511123B2
(en)
|
2011-10-18 |
2016-12-06 |
Csl Behring Gmbh |
Combined use of a sulfated glycosaminoglycan and a hyaluronidase for improving the bioavailability of factor VIII
|
|
CA2850579A1
(en)
|
2011-10-18 |
2013-04-25 |
Carsten Horn |
Method for improving the stability of purified factor viii after reconstitution
|
|
CN108465106B
(zh)
|
2012-01-12 |
2022-05-27 |
普吉特海湾血液中心 |
降低经受因子viii疗法的个体中针对因子viii的免疫原性的方法
|
|
PL2804623T3
(pl)
|
2012-01-12 |
2020-03-31 |
Bioverativ Therapeutics Inc. |
Chimeryczne polipeptydy czynnika viii i ich zastosowania
|
|
KR102097263B1
(ko)
|
2012-02-15 |
2020-04-06 |
바이오버라티브 테라퓨틱스 인크. |
Viii 인자 조성물 및 이를 제조하고 사용하는 방법
|
|
EP3549953A1
(en)
|
2012-02-15 |
2019-10-09 |
Bioverativ Therapeutics Inc. |
Recombinant factor viii proteins
|
|
EP2863940A4
(en)
|
2012-06-08 |
2016-08-10 |
Biogen Ma Inc |
CHIMERIC COAGULATION FACTORS
|
|
CN104519897A
(zh)
|
2012-06-08 |
2015-04-15 |
比奥根艾迪克Ma公司 |
促凝血化合物
|
|
US10023628B2
(en)
|
2012-07-06 |
2018-07-17 |
Bioverativ Therapeutics Inc. |
Cell line expressing single chain factor VIII polypeptides and uses thereof
|
|
KR101395736B1
(ko)
*
|
2012-07-10 |
2014-05-16 |
아주대학교산학협력단 |
인간 혈액응고인자 ⅷ 도메인 특이적 항체 및 이의 제조방법
|
|
CN104661674A
(zh)
|
2012-07-11 |
2015-05-27 |
阿穆尼克斯运营公司 |
具有xten和血管性血友病因子蛋白的因子viii复合物、及其用途
|
|
EP2877202A4
(en)
|
2012-07-25 |
2016-06-01 |
Biogen Ma Inc |
BLOOD FACTOR MONITORING TEST AND USES THEREOF
|
|
US10391152B2
(en)
|
2012-10-18 |
2019-08-27 |
Bioverativ Therapeutics Inc. |
Methods of using a fixed dose of a clotting factor
|
|
US20150266944A1
(en)
|
2012-10-30 |
2015-09-24 |
Biogen Idec Ma Inc. |
Methods of Using FVIII Polypeptide
|
|
HRP20210185T4
(hr)
|
2013-02-15 |
2024-10-11 |
Bioverativ Therapeutics Inc. |
Optimizirani gen faktora viii
|
|
TWI745671B
(zh)
|
2013-03-15 |
2021-11-11 |
美商百歐維拉提夫治療公司 |
因子ｉｘ多肽調配物
|
|
JP6330026B2
(ja)
|
2013-03-15 |
2018-05-23 |
バイオベラティブ セラピューティクス インコーポレイテッド |
第ｖｉｉｉ因子ポリペプチド製剤
|
|
DK2796145T3
(da)
|
2013-04-22 |
2018-01-29 |
Csl Ltd |
Et kovalent kompleks af von Willebrand-faktor og faktor VIII linket af en disulfidbro
|
|
KR102714760B1
(ko)
|
2013-06-28 |
2024-10-11 |
바이오버라티브 테라퓨틱스 인크. |
Xten을 지닌 트롬빈 절단가능한 링커 및 이의 용도
|
|
EP3043813B1
(en)
|
2013-08-08 |
2021-01-13 |
Bioverativ Therapeutics Inc. |
Purification of chimeric fviii molecules
|
|
US10548953B2
(en)
|
2013-08-14 |
2020-02-04 |
Bioverativ Therapeutics Inc. |
Factor VIII-XTEN fusions and uses thereof
|
|
EP3065769A4
(en)
|
2013-11-08 |
2017-05-31 |
Biogen MA Inc. |
Procoagulant fusion compound
|
|
EP4332839A3
(en)
|
2013-12-06 |
2024-06-05 |
Bioverativ Therapeutics Inc. |
Population pharmacokinetics tools and uses thereof
|
|
KR102409250B1
(ko)
|
2014-01-10 |
2022-06-14 |
바이오버라티브 테라퓨틱스 인크. |
인자 viii 키메라 단백질 및 이들의 용도
|
|
AU2015207472B2
(en)
*
|
2014-01-20 |
2018-11-22 |
Octapharma Ag |
A process for manufacturing factor VIII having an improved ratio of FVIII:C/FVIII:Ag
|
|
AU2015214245B2
(en)
|
2014-02-04 |
2020-09-10 |
Biogen Ma Inc. |
Use of cation-exchange chromatography in the flow-through mode to enrich post-translational modifications
|
|
AU2015299224B2
(en)
|
2014-08-04 |
2019-06-20 |
Csl Limited |
Factor VIII formulation
|
|
MA40864A
(fr)
|
2014-10-31 |
2017-09-05 |
Biogen Ma Inc |
Hypotaurine, gaba, bêta-alanine et choline pour la régulation de l'accumulation de sous-produits résiduaires dans des procédés de culture de cellules mammifères
|
|
BR112017018468A2
(pt)
|
2015-03-06 |
2018-04-17 |
Csl Behring Recombinant Facility Ag |
fator de von willebrand modificado com meia-vida aumentada
|
|
MX2017014872A
(es)
|
2015-05-22 |
2018-07-06 |
Csl Behring Recombinant Facility Ag |
Metodos para preparar factor de von willebrand modificado.
|
|
SG10201910896UA
(en)
|
2015-05-22 |
2020-01-30 |
CSL Behring Lengnau AG |
Truncated von willebrand factor polypeptides for treating hemophilia
|
|
MX2018001497A
(es)
|
2015-08-03 |
2018-05-15 |
Bioverativ Therapeutics Inc |
Proteinas de fusion de factor ix y metodos para producirlas y usarlas.
|
|
WO2017050820A1
(en)
*
|
2015-09-22 |
2017-03-30 |
Novo Nordisk A/S |
Fviii fusion proteins
|
|
BR112018009717B1
(pt)
|
2015-11-13 |
2021-12-14 |
Takeda Pharmaceutical Company Limited |
Polinucleotídeo, vetor de vírus adeno-associado, partícula de um vírus adeno-associado, métodos para produzir uma partícula de vírus adeno-associado e para transduzir uma célula hospedeira, e, uso de uma partícula de vírus adeno-associado
|
|
TWI823830B
(zh)
|
2015-11-13 |
2023-12-01 |
日商武田藥品工業股份有限公司 |
用於ａ型血友病基因治療之編碼表現增加之重組ｆｖｉｉｉ變異體之病毒載體
|
|
CN108472338B
(zh)
|
2016-01-07 |
2022-12-30 |
康诺贝林伦瑙有限公司 |
突变的截短的von Willebrand因子
|
|
JP7217630B2
(ja)
|
2016-02-01 |
2023-02-03 |
バイオベラティブ セラピューティクス インコーポレイテッド |
最適化第ｖｉｉｉ因子遺伝子
|
|
EP3476860A4
(en)
|
2016-06-24 |
2020-01-22 |
Mogam Institute for Biomedical Research |
Recombinant single-chain fviii and chemical conjugate thereof
|
|
EP3476937A4
(en)
|
2016-06-24 |
2019-12-04 |
Mogam Institute for Biomedical Research |
CHIMERIC PROTEIN WITH FVIII AND VWF FACTORS AND USE THEREOF
|
|
JP6351679B2
(ja)
*
|
2016-09-30 |
2018-07-04 |
エスケー ケミカルズ カンパニー リミテッド |
第ｖｉｉｉ因子とその誘導体の製造及び精製方法
|
|
ES2869339T3
(es)
|
2016-11-11 |
2021-10-25 |
CSL Behring Lengnau AG |
Polipéptidos del factor von Willebrand truncados para el tratamiento de la hemofilia
|
|
EP3538134B1
(en)
|
2016-11-11 |
2021-12-29 |
CSL Behring Lengnau AG |
Truncated von willebrand factor polypeptides for extravascular administration in the treatment or prophylaxis of a blood coagulation disorder
|
|
US12161696B2
(en)
|
2016-12-02 |
2024-12-10 |
Bioverativ Therapeutics Inc. |
Methods of treating hemophilic arthropathy using chimeric clotting factors
|
|
JP2019536794A
(ja)
|
2016-12-02 |
2019-12-19 |
バイオベラティブ セラピューティクス インコーポレイテッド |
凝固因子に対する免疫寛容を誘導する方法
|
|
CA3068098A1
(en)
|
2017-06-22 |
2018-12-27 |
CSL Behring Lengnau AG |
Modulation of fviii immunogenicity by truncated vwf
|
|
CN111247251A
(zh)
|
2017-08-09 |
2020-06-05 |
比奥维拉迪维治疗股份有限公司 |
核酸分子及其用途
|
|
US10793327B2
(en)
|
2017-10-09 |
2020-10-06 |
Terumo Bct Biotechnologies, Llc |
Lyophilization container and method of using same
|
|
JP2021512126A
(ja)
|
2018-02-01 |
2021-05-13 |
バイオベラティブ セラピューティクス インコーポレイテッド |
第ｖｉｉｉ因子を発現するレンチウイルスベクターの使用
|
|
EP3773517A1
(en)
|
2018-04-04 |
2021-02-17 |
Sigilon Therapeutics, Inc. |
Implantable particles and related methods
|
|
MX2020012397A
(es)
|
2018-05-18 |
2021-04-12 |
Bioverativ Therapeutics Inc |
Metodos de tratamiento de la hemofilia a.
|
|
BR112021000695A2
(pt)
|
2018-07-16 |
2021-04-20 |
Baxalta Incorporated |
métodos para tratar hemofilia a e para monitorar a eficácia da terapia gênica de fator viii de hemofilia a.
|
|
CN113227385B
(zh)
|
2018-08-09 |
2024-12-24 |
比奥维拉迪维治疗股份有限公司 |
核酸分子及其用于非病毒基因疗法的用途
|
|
WO2020061281A1
(en)
*
|
2018-09-19 |
2020-03-26 |
Cell Machines, Inc. |
Methods and compositions related to improved factor viii long half-life coagulation complexes
|
|
UY38389A
(es)
|
2018-09-27 |
2020-04-30 |
Sigilon Therapeutics Inc |
Dispositivos implantables para terapia celular y métodos relacionados
|
|
TWI851647B
(zh)
|
2019-01-16 |
2024-08-11 |
日商武田藥品工業股份有限公司 |
用於a型血友病基因治療之編碼表現增加之重組fviii變異體的病毒載體
|
|
MA54951A
(fr)
|
2019-02-15 |
2021-12-22 |
Bayer Healthcare Llc |
Édition de gène pour l'hémophilie a avec une expression de facteur viii améliorée
|
|
CA3130670A1
(en)
|
2019-03-14 |
2020-09-17 |
Terumo Bct Biotechnologies, Llc |
Lyophilization loading tray assembly and system
|
|
EP3736286A1
(en)
|
2019-05-09 |
2020-11-11 |
Biotest AG |
Single chain factor viii molecule
|
|
JP7585217B2
(ja)
|
2019-06-05 |
2024-11-18 |
クリスパー セラピューティクス アクチェンゲゼルシャフト |
改善された第ｖｉｉｉ因子発現による血友病ａのための遺伝子編集
|
|
AU2020298233A1
(en)
|
2019-06-19 |
2022-01-20 |
Bioverativ Therapeutics Inc. |
Recombinant factor VIII-Fc for treating hemophilia and low bone mineral density
|
|
EP3994162A1
(en)
|
2019-07-04 |
2022-05-11 |
CSL Behring Lengnau AG |
A truncated von willebrand factor (vwf) for increasing the in vitro stability of coagulation factor viii
|
|
EP4058049A1
(en)
|
2019-11-11 |
2022-09-21 |
CSL Behring Lengnau AG |
Polypeptides for inducing tolerance to factor viii
|
|
WO2021119357A2
(en)
|
2019-12-12 |
2021-06-17 |
Baxalta Incorporated |
Gene therapy of hemophilia a using viral vectors encoding recombinant fviii variants with increased expression
|
|
JP2021156833A
(ja)
*
|
2020-03-30 |
2021-10-07 |
シスメックス株式会社 |
血液凝固活性の測定方法
|
|
CA3183557A1
(en)
|
2020-06-24 |
2021-12-30 |
Bioverativ Therapeutics Inc. |
Methods for the removal of free factor viii from preparations of lentiviral vectors modified to express said protein
|
|
US20240269241A1
(en)
|
2021-06-14 |
2024-08-15 |
Takeda Pharmaceutical Company Limited |
Gene therapy of hemophilia a using viral vectors encoding recombinant fviii variants with increased expression
|
|
AR126846A1
(es)
|
2021-08-23 |
2023-11-22 |
Bioverativ Therapeutics Inc |
Genes del factor viii optimizados
|
|
CN118019758A
(zh)
|
2021-09-30 |
2024-05-10 |
比奥维拉迪维治疗股份有限公司 |
编码免疫原性降低的因子viii多肽的核酸
|
|
WO2024081309A1
(en)
|
2022-10-11 |
2024-04-18 |
Sigilon Therapeutics, Inc. |
Engineered cells and implantable elements for treatment of disease
|
|
WO2025008774A1
(en)
|
2023-07-05 |
2025-01-09 |
Takeda Pharmaceutical Company Limited |
Viral vectors encoding recombinant fviii variants with increased expression for gene therapy of hemophilia a
|